PMID- 37670301
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231121
IS  - 1475-2867 (Print)
IS  - 1475-2867 (Electronic)
IS  - 1475-2867 (Linking)
VI  - 23
IP  - 1
DP  - 2023 Sep 5
TI  - Safety and efficacy of T-cell-redirecting bispecific antibodies for patients with 
      multiple myeloma: a systematic review and meta-analysis.
PG  - 193
LID - 10.1186/s12935-023-03045-y [doi]
LID - 193
AB  - BACKGROUND: In recent years, several bispecific antibodies (BsAbs) have been 
      introduced that revolutionized the treatment approach for patients with multiple 
      myeloma (MM). In the present study, we sought for conducting a systematic review 
      and meta-analysis with the aim of evaluating the safety and efficacy of BsAbs in 
      MM patients. METHODS: PubMed, Scopus, Web of Science, and Embase databases were 
      systematically searched on June 10, 2022. Two steps of title/abstract and 
      full-text screening were performed for selecting the relevant articles. The 
      primary endpoint was considered to evaluate the safety of BsAbs by examining the 
      rate of hematologic and non-hematologic adverse effects (AEs). The secondary 
      outcome was set at the efficacy of BsAbs through pooling objective response rate 
      (ORR), (stringent) complete response (sCR/CR), very good partial response (VGPR), 
      and partial response (PR). RESULTS: Eleven publications with a total of nine 
      evaluable BsAbs were included for qualitative and quantitative data synthesis. 
      Hematologic AEs were more common among patients than non-hematologic events, with 
      the most frequent events being anemia (41.4%), neutropenia (36.4%), and 
      thrombocytopenia (26.3%). The most common non-hematological AE was infection, 
      which occurred in 39.9% of patients, followed by dysgeusia (28.3%), fatigue 
      (26.5%), and diarrhea (25.8%). Besides, 8.1% of patients experienced immune 
      effector cell-associated neurotoxicity syndrome and neurotoxicity occurred in 
      5.1% of them. Moreover, 59.8% of patients experienced cytokine release syndrome. 
      The pooled rate of deaths attributable to BsAbs was estimated at 0.1%. In terms 
      of efficacy measures, the ORR was achieved in 62.6% of MM patients, and the 
      pooled rates of sCR/CR, VGPR, and PR were 22.7%, 23.0%, and 12.1%, respectively. 
      CONCLUSIONS: In an era with several emerging promising treatments for MM, BsAbs 
      have achieved a high ORR and tolerable AEs in heavily pretreated patients. 
      However, there is still room for developing BsAbs with a lower rate of AEs and 
      capable of bypassing tumor evasion mechanisms.
CI  - (c) 2023. BioMed Central Ltd., part of Springer Nature.
FAU - Noori, Maryam
AU  - Noori M
AD  - Student Research Committee, School of Medicine, Iran University of Medical 
      Sciences, Tehran, Iran.
AD  - Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal 
      Scientific Education and Research Network (USERN), Tehran, Iran.
FAU - Yazdanpanah, Niloufar
AU  - Yazdanpanah N
AD  - Research Center for Immunodeficiencies, Children's Medical Center Hospital, 
      Tehran University of Medical Sciences, Dr. Qarib St, Keshavarz Blvd, 14194, 
      Tehran, Iran.
AD  - Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal 
      Scientific Education and Research Network (USERN), Tehran, Iran.
AD  - Student Research Committee, School of Medicine, Tehran University of Medical 
      Sciences, Tehran, Iran.
FAU - Rezaei, Nima
AU  - Rezaei N
AD  - Research Center for Immunodeficiencies, Children's Medical Center Hospital, 
      Tehran University of Medical Sciences, Dr. Qarib St, Keshavarz Blvd, 14194, 
      Tehran, Iran. rezaei_nima@tums.ac.ir.
AD  - Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal 
      Scientific Education and Research Network (USERN), Tehran, Iran. 
      rezaei_nima@tums.ac.ir.
AD  - Department of Immunology, School of Medicine, Tehran University of Medical 
      Sciences, Tehran, Iran. rezaei_nima@tums.ac.ir.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230905
PL  - England
TA  - Cancer Cell Int
JT  - Cancer cell international
JID - 101139795
PMC - PMC10478206
OTO - NOTNLM
OT  - Bispecific antibodies
OT  - BsAbs
OT  - Hematological
OT  - Multiple myeloma
OT  - Neutropenia
OT  - Relapse
OT  - anemia
COIS- The authors declare no competing interests.
EDAT- 2023/09/06 00:41
MHDA- 2023/09/06 00:42
PMCR- 2023/09/05
CRDT- 2023/09/05 23:43
PHST- 2023/06/24 00:00 [received]
PHST- 2023/08/28 00:00 [accepted]
PHST- 2023/09/06 00:42 [medline]
PHST- 2023/09/06 00:41 [pubmed]
PHST- 2023/09/05 23:43 [entrez]
PHST- 2023/09/05 00:00 [pmc-release]
AID - 10.1186/s12935-023-03045-y [pii]
AID - 3045 [pii]
AID - 10.1186/s12935-023-03045-y [doi]
PST - epublish
SO  - Cancer Cell Int. 2023 Sep 5;23(1):193. doi: 10.1186/s12935-023-03045-y.